Diabetic Dyslipidemia.
Conditions
Interventions
Intervention 1: Patients in this group will receive atorvastatin (20 mg, once a day) drug plus placebo for decrease of serum lipids for 3 months. Intervention 2: Patients in this group will receive at
Placebo
Treatment - Drugs
Patients in this group will receive atorvastatin (20 mg, once a day) drug plus placebo for decrease of serum lipids for 3 months.
Patients in this group will receive atrovastatin drug plus polyherbal compound. The compound is prepared as sachet (8.7g) containing powder of Allium sativum, Nigella sativa, Trigonella foenum, Psylli
Sponsors
Research Council of Mashhad University of Medical Sciences, Mashhad, IRAN
Eligibility
Sex/Gender
All
Age
25 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age: > 25 2. Non-insulin dependent diabetic patients 3. Fasting blood Sugar > 140 mg/dl and HbA1c > 7% 4. Serum Cholesterol > 200 mg/dl and Triglyceride > 150 mg/dl 5. Patients with chronic renal, hepatic or infectious diseases will be excluded. 6. Patients with history of any allergy to Garlic, Black seed, Aloe vera, fenugreek, Psyllium and Silybum marianum will be excluded. 7. No addiction to cigarette, alcohol or any other drugs.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cholestrol and triglyceride. Timepoint: At the begining of study as well as after1 and 3 months. Method of measurement: Standard Kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHassan Rakhshandeh
Mashhad University of Medical Sciences
Outcome results
None listed